Key result
Post-anthracycline changes in 18F-FDG PET/CT cardiac uptake and epicardial adipose tissue metabolism predict CTR-CVT.
Why the study?
To examine changes in 18F-FDG PET/CT cardiac uptake patterns and metabolic factors before and after anthracycline chemotherapy in lymphoma patients, and evaluate their value for chemotherapy-induced cardiac damage.
Do changes in 18F-FDG PET/CT cardiac uptake patterns and metabolic parameters predict cancer therapy-related cardiovascular toxicity in lymphoma patients receiving anthracycline-based chemotherapy?
Population
366 lymphoma patients receiving 6 cycles of anthracycline-based chemotherapy
Comparison
Post-treatment vs baseline 18F-FDG PET/CT scans and CTR-CVT vs non-CTR-CVT
Design
Retrospective cohort study
Follow-up
From chemotherapy initiation until January 2024
Authors
Loading...
May support PET/CT for early anthracycline cardiotoxicity prediction; hypothesis-generating and requires prospective validation.
Cohort (n=366)
No
Do changes in 18F-FDG PET/CT cardiac uptake patterns and metabolic parameters predict cancer therapy-related cardiovascular toxicity in lymphoma patients receiving anthracycline-based chemotherapy?
Changes in 18F-FDG PET/CT cardiac uptake patterns and epicardial adipose tissue metabolic parameters can serve as predictors for anthracycline-induced cardiovascular toxicity in lymphoma patients.
Lin et al. (2025) conducted a cohort in Lymphoma (n=366). Changes in 18F-FDG PET/CT cardiac uptake patterns and metabolic parameters vs. Normal changes / Non-CTR-CVT group was evaluated on Cancer therapy-related cardiovascular toxicity (CTR-CVT). Changes in 18F-FDG PET/CT cardiac uptake patterns and epicardial adipose tissue metabolic parameters after anthracycline-based chemotherapy predicted the occurrence of cardiovascular toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: